Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The effect of ranitidine on cellular immunity in patients with multiple myeloma.

Research output: Contribution to journalJournal articleResearch

  1. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

    Research output: Contribution to journalReviewResearchpeer-review

  2. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Research output: Contribution to journalReviewResearchpeer-review

  3. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting

    Research output: Contribution to journalReviewResearchpeer-review

  4. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

    Research output: Contribution to journalReviewResearchpeer-review

  5. Cancer immunotherapy in patients with brain metastases

    Research output: Contribution to journalReviewResearchpeer-review

  1. Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evaluation of algorithm development approaches: Development of biomarker panels for early detection of colorectal lesions

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genome-wide cell-free DNA fragmentation in patients with cancer

    Research output: Contribution to journalLetterResearchpeer-review

View graph of relations
Multiple myeloma is characterized by an increased susceptibility to infections and to other malignancies. In a double-blind, placebo-controlled study the potential impact of immunomodulation by ranitidine was studied in 20 patients with multiple myeloma. Three patients were untreated, while 17 after previous cytotoxic therapy were in a stable phase of their disease. All were without clinical signs of infections and at that time had not been treated with other immunomodulating agents. The patients were randomized to oral ranitidine 300 mg twice a day for 21 days or placebo, and several immunological parameters related to multiple myeloma were studied. The blood monocyte chemotactic response was improved in patients treated with ranitidine, and superoxide anion production increased from 2.02 nmol/min to 3.86 nmol/min (median values), while it was unchanged in patients given placebo (2.19-2.25 nmol/min) (P less than 0.005 between groups). Among ranitidine-treated patients spontaneous NK cell activity was unchanged, while in vitro interleukin-2- and interferon-alpha-stimulated NK cell activity decreased (P less than 0.03, respectively). As production of oxygen radicals constitutes an important mechanism of monocyte killing activity against microorganisms and probably against malignant cells, it is suggested that ranitidine may be of beneficial impact in the treatment of multiple myeloma.
Translated title of the contributionThe effect of ranitidine on cellular immunity in patients with multiple myeloma.
Original languageEnglish
JournalCancer Immunology, Immunotherapy
Volume32
Issue number3
Pages (from-to)201-205
Number of pages5
ISSN0340-7004
Publication statusPublished - 1990

ID: 32498847